Clinical Trial Update: Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. [Phase 2]

View source ↗

Summary

Open-label extension results from the Phase 2 PRESIDIO crossover study evaluating KZR-616 in polymyositis and dermatomyositis have been completed, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Polymyositis

Drugs mentioned

• KZR-616 (KZR-616)

Snippet

Sponsor: Kezar Life Sciences, Inc. | Conditions: Polymyositis, Dermatomyositis | Phase 2 | Status: COMPLETED | Results posted: 2024-06-05